Shares in drugmakers AstraZeneca (AZN.L) and Shire (SHP.L) both fell more than 5 percent on Tuesday after the U.S. Treasury took steps to curb "inversion" deals that allow companies to escape high U.S. taxes by reincorporating abroad.
Tags: Pfizer
AstraZeneca CEO says new Pfizer bid unlikely
U.S. Pfizer is unlikely to come back with a fresh bid for AstraZeneca, the Anglo-Swedish pharmaceuticals group's top executive was quoted as saying by Swedish business daily Dagens Industri on Saturday.
Pfizer dampens Astra bid hopes with German Merck cancer deal
Pfizer (PFE.N) dampened investors' expectations of a renewed bid for AstraZeneca (AZN.L) on Monday by signing a major cancer drug deal with Germany's Merck KGaA (MRCG.DE), reducing the U.S. firm's need for Astra's products.
Tax changes weaken case for new Pfizer bid, says AstraZeneca CEO
Recent U.S. tax changes have weakened the case for companies like Pfizer (PFE.N) to shift their tax bases overseas by striking so-called tax inversion deals, according to AstraZeneca's (AZN.L) chief executive.
Drugmakers may need indemnity for fast-tracked Ebola vaccines
Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa.
Latest News
U.S. fund managers are finding a lot to like about finger-painting and naptime. Fund ownership of Bright Horizons Family Solutions Inc, the only publicly traded daycare company in the United States, swelled 21 percent in the most recently reported quarter according to fund tracker Morningstar.
Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Instead, he has spent the last three days immersed in heart science in Barcelona.
Oklahoma, US-based anti-abortion craft store chain Hobby Lobby stirred controversy by investing $73 million in Pfizer, Bayer, and other companies that make abortive drugs and contraception.
After lackluster activity in the past years, pharmaceutical firms have gotten back to producing new drugs but they encounter challenges in selling them, according to a report on The Wall Street Journal.
Ben Venue Laboratories, a subsidiary of German Boehringer Ingelheim in the US, has engaged Bank of American Merill Lynch to advise it on a proposed sale of its sterile injectable drugs business.
Merck & Co. decided to cut its annual spending by USD2.5 billion and eliminate more than 10% of its global workers.
Pharmaceutical giants Pfizer, AstraZeneca and Novartis are among those to propose bids for Onyx Pharmaceuticals.
Pfizer invests in two plants in Ireland. A company restructuring in Pfizer's two plants went underway as the pharmaceutical giant announced that a US$130 million investment is heading their way.
Pharmaceutical giant Pfizer Inc. (PFE) announced it had reached a settlement worth $2.15 billion with Teva Pharmaceutical Industries Ltd. (TEVA) and Sun Pharmaceutical Industries Ltd. (SUNP) after almost a decade of trials over Protonix sales in the United States.
